Eli Lilly Announces $27 Billion Investment to Build Four New Drug Manufacturing Facilities in the U.S.

Source: Cailian Press

On Wednesday local time, the U.S. pharmaceutical giantEli LillyThe company announced that it will invest at least $27 billion to build four new production bases in the United States. During the U.S. stock trading session, the share price of Eli Lilly and Company rose by 0.4%.

The demand for Eli Lilly's weight-loss and diabetes drugs continues to rise in the market. Additionally, the company is developing new drugs for other diseases to diversify its product line and strengthen its position in the pharmaceutical industry.

Meanwhile, major pharmaceutical companies are striving to build good relationships with the newly elected President Trump, who has repeatedly emphasized the issue of "bringing manufacturing back to the United States," aiming to reduce reliance on foreign supply chains and enhance the manufacturing capabilities of the U.S.

Notably, Eli Lilly and Company announced this news at an event in Washington, D.C., highlighting the political undertones of its investment strategy. Analysts suggest that Eli Lilly is undoubtedly sending a positive signal to the Trump administration — demonstrating the company’s support for the revival of American manufacturing and hoping to gain favorable backing from the government in return.

This move has brought Eli Lilly's investments in manufacturing to over 50 billion US dollars in recent years. Prior to this, Eli Lilly had announced an investment of 23 billion US dollars to build and expand its manufacturing sites in the United States and Europe, which helped alleviate supply shortages of its best-selling drugs.

It is reported that among the four planned production bases, three will focus on producing active pharmaceutical ingredients and further strengthening the supply chain, such as the active ingredient tirzepatide for the weight-loss drug Zepbound and the diabetes treatment Mounjaro. The fourth production base will concentrate on future injection therapies.

The new investment is not only for Eli Lilly's current and future obesity and diabetes treatment drugs, but the company is also planning for the future by actively expanding into broader therapeutic areas, including cancer, Alzheimer's disease, etc., which will enhance its competitiveness in the global pharmaceutical market.

Eli Lilly and Company CEO David Ricks said in a statement on Wednesday: "We are confident in the potential of our R&D pipeline across multiple therapeutic areas, including cardiometabolic health, oncology, immunology, and neuroscience, which drives our unprecedented commitment to expanding manufacturing capacity in China."

Nevertheless, the new investment still builds on the success of Zepbound and Mounjaro, both of which are...Novo NordiskWegovy, a weight-loss drug, and Ozempic, a diabetes medication, together dominate the GLP-1 class drug market.

Some analysts predict that in the next decade, the global weight-loss drug market will exceed $150 billion annually. Therefore, it is crucial for these two companies to maintain their market share as other pharmaceutical manufacturers rush to enter this field.

Ricks added that the latest news also reflects the company's commitment to staying at the forefront and ensuring it can meet the ever-growing demand from consumers and healthcare institutions for high-quality medicines.

Eli Lilly and Company anticipates that the new production base will create over 3,000 high-skilled positions, including engineers, scientists, operators, and laboratory technicians. Additionally, the company expects to generate nearly 10,000 construction jobs during the factory's development phase.

Editor: Li Tong